Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Medicure, Manchester Securities Corp. deal

MPH sold a percentage of its current and potential future commercial revenues to Manchester, a subsidiary

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE